Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemia

Blood (2011) 118 (13): 3634–3644.

https://doi.org/10.1182/blood-2011-03-341073

Published: 2011

Includes: Supplemental data

Journal Articles

Clinical Pharmacokinetics of Intravenous and Oral MLN9708, An Investigational Proteasome Inhibitor: An Analysis of Data From Four Phase 1 Monotherapy Studies

Neeraj Gupta, Guohui Liu, Debbie Berg, Thea Kalebic, Jesus Gomez-Navarro

Blood (2010) 116 (21): 1813.

https://doi.org/10.1182/blood.V116.21.1813.1813

Published: 2010

Journal Articles

C-Myc Mediated Regulation of Multidrug Resistance Genes in Chronic Myeloid Leukaemia Cd34+ Cell Progenitors.

Samuele Gherardi, Simona Soverini, Ph.D., Nunzio Iraci, Ph.D., Carolina Terragna, Ph.D., Emanuele Valli, Sandra Durante, Annalisa Astolfi, Ph.D., Roberto Bernardoni, Ph.D., Thea Kalebic, MD, Fabrizio Pane, MD, Giuseppe Saglio, MD, Giovanni Martinelli, MD, Michele Baccarani, MD, Giovanni Perini, Ph.D.

Blood (2009) 114 (22): 3252.

https://doi.org/10.1182/blood.V114.22.3252.3252

Published: 2009

Journal Articles

Identification of Rab5 as a Gene Involved in Chronic Myeloid Leukemia (CML) Progression.

Daniela Cilloni, MD, PhD, Monica Pradotto, PhD, Francesca Messa, PhD, Francesca Arruga, PhD, Enrico Bracco, PhD, Sonia Carturan, PhD, Chiara Maffè, PhD, Emanuela Messa, MD, Antonia Rotolo, MD, Elisabetta Greco, MD, Ilaria Iacobucci, PhD, Thea Kalebic, MD, Roberto Bernardoni, Fabrizio Pane, MD, Giovanni Martinelli, MD, Michele Baccarani, M.D., Giuseppe Saglio, MD

Blood (2009) 114 (22): 3470.

https://doi.org/10.1182/blood.V114.22.3470.3470

Published: 2009

Journal Articles

Quantitative PCR Using a Nanofluidic Platform to Quantify Bcr-Abl mRNA in Patients Who Are Negative by Routine Quantitative PCR Testing.

Vivian G. Oehler, Bret Helton, Thea Kalebic, Jerald P. Radich

Blood (2009) 114 (22): 3300.

https://doi.org/10.1182/blood.V114.22.3300.3300

Published: 2009

Journal Articles

Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.

Blood (2009) 114 (22): 3283.

https://doi.org/10.1182/blood.V114.22.3283.3283

Published: 2009

Journal Articles

Disabled Gene Is Involved in CML Progression and Its Expression Level at Diagnosis Can Predict Major Molecular Response (MMR) to Imatinib Therapy.

Daniela Cilloni, MD, PhD, Francesca Arruga, PhD, Francesca Messa, PhD, Monica Pradotto, PhD, Enrico Bracco, PhD, Sonia Carturan, PhD, Chiara Maffè, PhD, Emanuela Messa, MD, Antonia Rotolo, MD, Elisabetta Greco, MD, Ilaria Iacobucci, PhD, Roberto Bernardoni, Fabrizio Pane, MD, Thea Kalebic, MD, Giovanni Martinelli, Michele Baccarani, MD, Giuseppe Saglio, MD

Blood (2009) 114 (22): 3964.

https://doi.org/10.1182/blood.V114.22.3964.3964

Published: 2009

Journal Articles

Suppression of Bcr-Abl Expression in CML by A Panel of miRNAs.

Nunzio Iraci, Ph.D., Emanuele Valli, Samuele Gherardi, Simona Soverini, PhD, Thea Kalebic, M.D., Michele Baccarani, M.D., Giovanni Martinelli, M.D., Giovanni Perini, Ph.D.

Blood (2009) 114 (22): 854.

https://doi.org/10.1182/blood.V114.22.854.854

Published: 2009

Journal Articles

Bcr-Abl Kinetics Suggest Self-Renewing Leukemic Cells Are Reduced During Imatinib Treatment.

Andrew Stein, PhD, Thea Kalebic, MD, Dean Bottino, PhD

Blood (2009) 114 (22): 506.

https://doi.org/10.1182/blood.V114.22.506.506

Published: 2009

Journal Articles

Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients.

Blood (2009) 114 (22): 2212.

https://doi.org/10.1182/blood.V114.22.2212.2212

Published: 2009

Journal Articles

CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.

Carolina Terragna, Sandra Durante, Annalisa Astolfi, Francesca Palandri, Fausto Castagnetti, Gianantonio Rosti, Nicoletta Testoni, Simona Luatti, Ilaria Iacobucci, PhD, Thea Kalebic, MD, Simona Soverini, Marilina Amabile, Angela Poerio, Michele Baccarani, Giovanni Martinelli

Blood (2009) 114 (22): 2174.

https://doi.org/10.1182/blood.V114.22.2174.2174

Published: 2009

Journal Articles

Imatinib Induced Re-Activation of FoxO3 Transcription Factor in CML Is Responsible for the Induction of a Quiescent Status of CD34 Leukaemic Progenitor Cells.

Daniela Cilloni, MD, PhD, Cristina Panuzzo, PhD, Francesca Messa, PhD, Francesca Arruga, PhD, Enrico Bracco, PhD, Roberto Bernardoni, PhD, Sonia Carturan, PhD, Marisa Pautasso, MD, Emanuela Messa, MD, Alessandro Morotti, MD, Monica Pradotto, PhD, Ilaria Iacobucci, Thea Kalebic, MD, Giovanni Martinelli, MD, Giuseppe Saglio, MD

Blood (2008) 112 (11): 1090.

https://doi.org/10.1182/blood.V112.11.1090.1090

Published: 2008

Journal Articles

Identification of Genes Sustaining Bcr-Abl Oncogenic Signalling and CML Progression through a Genetic Tool Based on Human Bcr-Abl Transgenic Drosophila Melanogaster.

Daniela Cilloni, Francesca Messa, PhD, Roberto Bernardoni, PhD, Francesca Arruga, PhD, Monica Pradotto, PhD, Enrico Bracco, PhD, Cristina Panuzzo, PhD, Chiara Maffè, PhD, Emanuela Messa, MD, Ilaria Iacobucci, Thea Kalebic, MD, Giovanni Martinelli, MD, Michele Baccarani, MD, Giuseppe Saglio, MD

Blood (2008) 112 (11): 1091.

https://doi.org/10.1182/blood.V112.11.1091.1091

Published: 2008

Journal Articles

EphA3 Kinase Is Constitutively Activated in Chronic Myeloid Leukaemia during Progression to Accelerated and Blast Crisis and It Could Represent a New Molecular Target.

Daniela Cilloni, MD, PhD, Francesca Arruga, PhD, Sonia Carturan, PhD, Francesca Messa, PhD, Monica Pradotto, PhD, Ilaria Defilippi, PhD, Marisa Pautasso, MD, Ilaria Iacobucci, PhD, Giovanni Martinelli, MD, Enrico Bracco, PhD, Thea Kalebic, MD, Martin Lackmann, PhD, Giuseppe Saglio, MD

Blood (2008) 112 (11): 1092.

https://doi.org/10.1182/blood.V112.11.1092.1092

Published: 2008

Journal Articles

The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial.

Nicola Esposito, PhD, Fabrizio Quarantelli, Luigia Luciano, MD, Barbara Izzo, PhD, Anna Lucia Peluso, PhD, Marco Picardi, MD, Susan Branford, PhD, D.L. White, PhD, Timothy Hughes, PhD, Jerald Radich, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Giuseppe Saglio, MD, Thea Kalebic, PhD, Mark Thornquist, PhD, Giovanni Martinelli, MD, Fabrizio Pane, MD

Blood (2008) 112 (11): 1106.

https://doi.org/10.1182/blood.V112.11.1106.1106

Published: 2008

Journal Articles

The IC50 Assay Is Predictive of Molecular Response, and Indicative of Optimal Dose in De-Novo CML Patients.

Deborah L White, PhD, Verity A Saunders, Thea Kalebic, MD, Timothy P Hughes, MD

Blood (2008) 112 (11): 1109.

https://doi.org/10.1182/blood.V112.11.1109.1109

Published: 2008

Journal Articles

A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment

Nicola Esposito, PhD, Irene Colavita, PhD, Fabrizio Quarantelli, PhD, Barbara Izzo, PhD, Luigia Luciano, MD, Luigi Del Vecchio, MD, Timothy Hughes, Jerald Radich, Domenico Russo, MD, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Giovanni Martinelli, MD, Giuseppe Saglio, MD, Junia Melo, MD, PhD, Margherita Ruoppolo, PhD, Thea Kalebic, Fabrizio Pane, MD

Blood (2008) 112 (11): 3186.

https://doi.org/10.1182/blood.V112.11.3186.3186

Published: 2008

Journal Articles

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

Deborah L White, PhD, Verity A Saunders, Phuong Dang, Amity Frede, Laura Eadie, Simona Soverini, PhD, Fabrizio Quarantelli, Peter Lin, Mark Thornquist, Dong-Wook Kim, MD, PhD, Fabrizio Pane, MD, Giovanni Martinelli, Jerald Radich, Thea Kalebic, MD, Giuseppe Saglio, MD, Timothy Hughes, MD

Blood (2008) 112 (11): 3187.

https://doi.org/10.1182/blood.V112.11.3187.3187

Published: 2008

Journal Articles

Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score

Carolina Terragna, Sandra Durante, Annalisa Astolfi, Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Simona Luatti, Gianantonio Rosti, Marilina Amabile, Angela Poerio, Ilaria Iacobucci, Simona Soverini, Thea Kalebic, MD, Michele Baccarani, Giovanni Martinelli

Blood (2008) 112 (11): 3190.

https://doi.org/10.1182/blood.V112.11.3190.3190

Published: 2008

Journal Articles

FoxO Transcription Factor Is Delocalized in CML Patients by Bcr-Abl Induced PI3K/AKT Activation and IKK Pathway and Can Be Reactivated by Imatinib Treatment.

Daniela Cilloni, MD, PhD, Cristina Panuzzo, PhD, Francesca Messa, PhD, Francesca Arruga, PhD, Paolo Nicoli, MD, Emanuela Messa, MD, Stefano Ulisciani, MD, Ilaria Iacobucci, PhD, Giovanni Martinelli, MD, Enrico Bracco, PhD, Thea Kalebic, MD, Giuseppe Saglio, MD

Blood (2007) 110 (11): 1010.

https://doi.org/10.1182/blood.V110.11.1010.1010

Published: 2007

NARROW

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemia

Clinical Pharmacokinetics of Intravenous and Oral MLN9708, An Investigational Proteasome Inhibitor: An Analysis of Data From Four Phase 1 Monotherapy Studies

C-Myc Mediated Regulation of Multidrug Resistance Genes in Chronic Myeloid Leukaemia Cd34+ Cell Progenitors.

Identification of Rab5 as a Gene Involved in Chronic Myeloid Leukemia (CML) Progression.

Quantitative PCR Using a Nanofluidic Platform to Quantify Bcr-Abl mRNA in Patients Who Are Negative by Routine Quantitative PCR Testing.

Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.

Disabled Gene Is Involved in CML Progression and Its Expression Level at Diagnosis Can Predict Major Molecular Response (MMR) to Imatinib Therapy.

Suppression of Bcr-Abl Expression in CML by A Panel of miRNAs.

Bcr-Abl Kinetics Suggest Self-Renewing Leukemic Cells Are Reduced During Imatinib Treatment.

Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients.

CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.

Imatinib Induced Re-Activation of FoxO3 Transcription Factor in CML Is Responsible for the Induction of a Quiescent Status of CD34 Leukaemic Progenitor Cells.

Identification of Genes Sustaining Bcr-Abl Oncogenic Signalling and CML Progression through a Genetic Tool Based on Human Bcr-Abl Transgenic Drosophila Melanogaster.

EphA3 Kinase Is Constitutively Activated in Chronic Myeloid Leukaemia during Progression to Accelerated and Blast Crisis and It Could Represent a New Molecular Target.

The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial.

The IC50 Assay Is Predictive of Molecular Response, and Indicative of Optimal Dose in De-Novo CML Patients.

A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score

FoxO Transcription Factor Is Delocalized in CML Patients by Bcr-Abl Induced PI3K/AKT Activation and IKK Pathway and Can Be Reactivated by Imatinib Treatment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only